Patent 9994537 was granted and assigned to Abide Therapeutics on June, 2018 by the United States Patent and Trademark Office.
Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.